Modeling biological rhythms in failure time data

Journal of Circadian Rhythms

Volumn 4, Issue , 2006, Pages

  Elkum, Naser B ^a   Myles, James D ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; BIOLOGICAL RHYTHM; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MATHEMATICAL MODEL; MENSTRUAL CYCLE; PREDICTION; PREMENOPAUSE; PREOPERATIVE EVALUATION; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; TUMOR VOLUME;

EID: 33751231442     PISSN: 17403391     EISSN: 17403391     Source Type: Journal    
DOI: 10.1186/1740-3391-4-14     Document Type: Article

References (34)

1. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Herait P, Bleiberg H: Clinical activity and benefit of irinotecan (CPT-II) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999, 35(1):54-59.
2. Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathe G: Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 1990, 8(4):705-714.
3. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82(12):1046-1050.
4. Depres-Brummer P, Levi F, Di Palma M, Beliard A, Lebon P, Marion S, Jasmin C, Misset JL: A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. J Immunother 1991, 10(6):440-447.
5. Depres-Brummer P, Berthault-Cvitkovic F, Levi F, Brienza S, Vannetzel JM, Jasmin C, Misset JL: Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial. J Infus Chemother 1995, 5(3 Suppl I): 144-147.
6. Halberg F, Cornelissen G, Wang Z, Wan C, Ulmer W, Katinas G, Singh R, Singh RK, Singh RK, Gupta BD, Singh RB, Kumar A, Kanabrocki E, Sothern RB, Rao G, Bhatt ML, Srivastava M, Rai G, Singh S, Pati AK, Nath P, Halberg F, Halberg J, Schwartzkopff O, Bakken E, Governor Shri Vishnu Kant S: Chronomics: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceuticals and beyond. J Exp Ther Oncol 2003, 3(5):223-260.
7. Tong YL: Parameter estimation in studying circadian rhythms. Biometrics 1976, 32(1):85-94.
8. Ware JH, Bowden RE: Circadian rhythm analysis when output is collected at intervals. Biometrics 1977, 33(3):566-571.
9. Nelson W, Tong YL, Lee JK, Halberg F: Methods for cosinor-rhythmometry. Chronobiologia 1979, 6(4):305-323.
10. Hickey DS, Kirkland JL, Lucas SB, Lye M: Analysis of circadian rhythms by fitting a least squares sine curve. Comput Biol Med 1984, 14(2):217-223.
11. Wang Y, Brown MB: A flexible model for human circadian rhythms. Biometrics 1996, 52(2):588-596.
12. Wang Y, Ke C, Brown MB: Shape-invariant modeling of circadian rhythms with random effects and smoothing spline ANOVA decompositions. Biometrics 2003, 59(4):804-812.
13. Halberg F: Chronobiology: methodological problems. Acta med rom 1980, 18:399-440.
14. Cornelissen G, Halberg F: Chronomedicine. In Encyclopedia of Biostatistics Edited by: Armitage P, Colton T. Chicheter, UK, John Wiley & Sons Ltd; 2005:796-812.
15. Cox D: Regression Models and Life Tables. Journal of the Royal Statistical Society 1972, B34:187-220.
16. Kendall M, Stuart A: The advanced Theory of Statistics. Volume I. London, Griffin; 1986.
17. Tibshirani R, Hastie T: Local likelihood estimation. JASA 1987, 82:559-567.
18. Efron B: Computer-intensive methods in statistical regression. SIAM Review 1988, 30:421-449.
19. Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ: Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther 2003, 2(2):105-111.
20. Levi F: Circadian chronotherapy for human cancers. Lancet Oncol 2001, 2(5):307-315.
21. Hrushesky WJ: Rhythmic menstrual cycle modulation of breast cancer biology. J Surg Oncol 2000, 74(3):238-241.
22. Wood PA, Hrushesky WJ: Circadian rhythms and cancer chemotherapy. Crit Rev Eukaryot Gene Expr 1996, 6(4):299-343.
23. Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa P: Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res 2004, 6(6):R689-96.
24. Zurrida S, Galimberti V, Gibelli B, Luini A, Gianoglio S, Sandri MT, Passerini R, Maisonneuve P, Zucali P, Jeronesi G, Pigatto F, Veronesi U: Timing of breast cancer surgery in relation to the menstrual cycle: an update of developments. Crit Rev Oncol Hematol 2001, 38(3):223-230.
25. Saad Z, Bramwell V, Duff J, Girotti M, Jory T, Heathcote G, Turnbull I, Garcia B, Stitt L: Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg 1994, 81(2):217-220.
26. Senie RT, Rosen PP, Rhodes P, Lesser ML: Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 1991, 115(5):337-342.
27. Hrushesky WJ, Bluming AZ, Gruber SA, Sothern RB: Menstrual influence on surgical cure of breast cancer. Lancet 1989, 2(8669):949-952.
28. Spratt JS, Zirnheld J, Yancey JM: Breast Cancer Detection Demonstration Project data can determine whether the prognosis of breast cancer is affected by the time of surgery during the menstrual cycle. J Surg Oncol 1993, 53(1):4-9.
29. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD, Fentiman IS: Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991, 337(8752):1261-1264.
30. Goldhirsch A, Gelber R, Forbes J: Timing breast cancer surgery. Lancet 1991, 338(8768):691-693.
31. Nomura Y, Kataoka A, Tsutsui S, Murakami S, Takenaka Y: Lack of correlation between timing of surgery in relation to the menstrual cycle and prognosis of premenopausal patients with early breast cancer. Eur J Cancer 1999, 35(9):1326-1330.
32. Milella M, Nistico C, Ferraresi V, Vaccaro A, Fabi A, D'Ottavio AM, Botti C, Giannarelli D, Lopez M, Cortesi E, Foggi CM, Antimi M, Terzoli E, Cognetti F, Papaldo P: Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. Breast Cancer Res Treat 1999, 55(3):259-266.
33. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams C, Tu D: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. Journal of Clinical Oncology 1998, 16(8):2651-2658.
34. Fehring RJ, Schneider M, Raviele K: Variability in the phases of the menstrual cycle. J Obstet Gynecol Neonatal Nurs 2006, 35(3):376-384.